{"entity":{"id":"paper-portec-3-molecular-leon-castillo-jco-2020","kind":"paper","name":"Molecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group","aka":[],"tldr":"Re-analysing the PORTEC-3 trial by molecular class showed that p53-abnormal endometrial cancers gained substantially from adding chemotherapy to radiotherapy, POLE-mutated tumours did well regardless, and the other groups gained little.","summary":"Molecular classification of 410 high-risk endometrial cancers from the PORTEC-3 trial (chemoradiotherapy versus radiotherapy) into p53-abnormal, POLE-mutated, mismatch repair-deficient and no specific molecular profile groups.\n\nFive-year recurrence-free survival for p53-abnormal tumours was 59 percent with chemoradiotherapy against 36 percent with radiotherapy alone; POLE-mutated tumours had 96 to 100 percent recurrence-free survival in both arms; mismatch repair-deficient and no specific molecular profile groups showed no significant benefit from chemotherapy.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2020","url":"https://doi.org/10.1200/JCO.20.00549"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32749941/"}],"tags":[],"related":[],"cancers":["endometrial-mmr-deficient","endometrial-p53-abnormal","endometrial-pole-ultramutated"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["portec-3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2020,"doi":"10.1200/JCO.20.00549","pmid":"32749941","authors":"León-Castillo A, de Boer SM, Powell ME, et al.","paperType":"translational","findings":["p53-abnormal: five-year recurrence-free survival 59 percent vs 36 percent with chemoradiotherapy vs radiotherapy.","POLE-mutated: recurrence-free survival 96 to 100 percent regardless of treatment."],"whatItMeans":"Molecular class is now a predictive factor for adjuvant therapy: chemotherapy for p53-abnormal disease, de-escalation for POLE-mutated tumours, and trials of immunotherapy for mismatch repair-deficient disease.","caveats":["Retrospective subgroup analysis with small molecular groups.","Confirmation is being sought in the RAINBO programme."],"changedPractice":true,"participants":410},"route":"/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/","neighbours":{"cancer":[{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/"},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"},{"id":"endometrial-pole-ultramutated","kind":"cancer","name":"POLE-ultramutated endometrial cancer","route":"/cancers/endometrial-pole-ultramutated/"}],"trial":[{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}